Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 186 | 2024 | 11879 | 8.230 |
Why?
|
Heart Transplantation | 54 | 2024 | 3301 | 5.530 |
Why?
|
Heart-Assist Devices | 42 | 2024 | 1292 | 5.370 |
Why?
|
Xanthines | 30 | 2018 | 121 | 3.970 |
Why?
|
Diuretics | 40 | 2021 | 614 | 3.360 |
Why?
|
Adenosine A1 Receptor Antagonists | 11 | 2018 | 27 | 1.820 |
Why?
|
Stroke Volume | 44 | 2024 | 5622 | 1.670 |
Why?
|
Tissue Donors | 12 | 2024 | 2381 | 1.420 |
Why?
|
Peripartum Period | 8 | 2023 | 137 | 1.420 |
Why?
|
Cardiomyopathies | 15 | 2023 | 2057 | 1.380 |
Why?
|
Hyperuricemia | 3 | 2021 | 222 | 1.340 |
Why?
|
Allopurinol | 4 | 2021 | 202 | 1.320 |
Why?
|
Pregnancy Complications, Cardiovascular | 5 | 2019 | 519 | 1.320 |
Why?
|
Xanthine Oxidase | 6 | 2021 | 69 | 1.320 |
Why?
|
Cardiomyopathy, Dilated | 8 | 2018 | 843 | 1.280 |
Why?
|
Ventricular Function, Left | 23 | 2023 | 3941 | 1.190 |
Why?
|
Societies, Medical | 15 | 2019 | 3968 | 1.130 |
Why?
|
Hospitalization | 37 | 2022 | 10840 | 1.060 |
Why?
|
Consensus | 14 | 2020 | 3211 | 1.060 |
Why?
|
Aspirin | 5 | 2024 | 3135 | 1.030 |
Why?
|
Renal Insufficiency | 11 | 2019 | 812 | 1.010 |
Why?
|
Furosemide | 8 | 2016 | 174 | 1.000 |
Why?
|
Cardiotonic Agents | 8 | 2020 | 543 | 0.980 |
Why?
|
Tissue and Organ Procurement | 6 | 2024 | 986 | 0.970 |
Why?
|
Acute Disease | 51 | 2021 | 7243 | 0.960 |
Why?
|
Cardiovascular Agents | 5 | 2017 | 849 | 0.940 |
Why?
|
Patient Selection | 11 | 2019 | 4260 | 0.930 |
Why?
|
Natriuretic Peptide, Brain | 19 | 2022 | 1751 | 0.920 |
Why?
|
Vasodilator Agents | 11 | 2016 | 990 | 0.900 |
Why?
|
Purinergic P1 Receptor Antagonists | 5 | 2017 | 45 | 0.890 |
Why?
|
Hemodynamics | 16 | 2021 | 4194 | 0.870 |
Why?
|
Waiting Lists | 8 | 2022 | 779 | 0.820 |
Why?
|
Warfarin | 5 | 2024 | 1493 | 0.820 |
Why?
|
Kidney | 17 | 2021 | 7064 | 0.800 |
Why?
|
Free Radical Scavengers | 2 | 2021 | 213 | 0.780 |
Why?
|
Angiotensin Receptor Antagonists | 6 | 2022 | 1065 | 0.780 |
Why?
|
Humans | 265 | 2024 | 768171 | 0.750 |
Why?
|
Registries | 11 | 2023 | 8375 | 0.740 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 4 | 2021 | 252 | 0.740 |
Why?
|
S-Adenosylhomocysteine | 1 | 2021 | 40 | 0.740 |
Why?
|
Patient Readmission | 14 | 2019 | 3288 | 0.710 |
Why?
|
Heart Diseases | 6 | 2020 | 2819 | 0.690 |
Why?
|
Ventricular Dysfunction, Left | 12 | 2019 | 2145 | 0.690 |
Why?
|
American Heart Association | 8 | 2019 | 1050 | 0.680 |
Why?
|
Renin-Angiotensin System | 5 | 2019 | 737 | 0.670 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 9 | 2022 | 1515 | 0.660 |
Why?
|
S-Adenosylmethionine | 1 | 2021 | 219 | 0.660 |
Why?
|
Creatinine | 15 | 2018 | 1918 | 0.650 |
Why?
|
Pulmonary Artery | 6 | 2021 | 1946 | 0.640 |
Why?
|
Patient Rights | 1 | 2019 | 126 | 0.630 |
Why?
|
Emergency Medicine | 5 | 2020 | 1223 | 0.630 |
Why?
|
Treatment Outcome | 64 | 2024 | 65379 | 0.630 |
Why?
|
Graft Rejection | 11 | 2021 | 4492 | 0.600 |
Why?
|
Kidney Diseases | 8 | 2019 | 2100 | 0.590 |
Why?
|
Blood Pressure Determination | 2 | 2022 | 646 | 0.590 |
Why?
|
Telemedicine | 3 | 2020 | 3109 | 0.570 |
Why?
|
Coronavirus Infections | 6 | 2020 | 3115 | 0.570 |
Why?
|
Medication Therapy Management | 2 | 2017 | 131 | 0.560 |
Why?
|
Pneumonia, Viral | 6 | 2020 | 3238 | 0.560 |
Why?
|
Practice Guidelines as Topic | 14 | 2024 | 7454 | 0.560 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2016 | 374 | 0.540 |
Why?
|
Cardiac Output, Low | 4 | 2006 | 192 | 0.540 |
Why?
|
Middle Aged | 125 | 2024 | 223487 | 0.540 |
Why?
|
Quality of Life | 18 | 2022 | 13490 | 0.540 |
Why?
|
Cardiology | 8 | 2019 | 1702 | 0.540 |
Why?
|
Eligibility Determination | 2 | 2019 | 421 | 0.530 |
Why?
|
Prisoners | 1 | 2019 | 316 | 0.520 |
Why?
|
Emergencies | 2 | 2019 | 1221 | 0.510 |
Why?
|
Adrenergic beta-Antagonists | 5 | 2024 | 1243 | 0.510 |
Why?
|
Myocardium | 10 | 2018 | 4790 | 0.510 |
Why?
|
Exercise Tolerance | 6 | 2020 | 846 | 0.500 |
Why?
|
Emergency Treatment | 1 | 2019 | 497 | 0.500 |
Why?
|
Heart Ventricles | 10 | 2020 | 3841 | 0.500 |
Why?
|
Expert Testimony | 1 | 2017 | 266 | 0.490 |
Why?
|
Ventricular Dysfunction, Right | 2 | 2012 | 646 | 0.490 |
Why?
|
Male | 144 | 2024 | 364731 | 0.480 |
Why?
|
Double-Blind Method | 32 | 2023 | 12466 | 0.480 |
Why?
|
Postoperative Complications | 10 | 2024 | 15833 | 0.480 |
Why?
|
Hepatitis C | 3 | 2022 | 1595 | 0.480 |
Why?
|
Patient Discharge | 8 | 2019 | 3479 | 0.480 |
Why?
|
Prosthesis Implantation | 1 | 2019 | 594 | 0.470 |
Why?
|
Female | 146 | 2024 | 397187 | 0.470 |
Why?
|
Myocardial Contraction | 5 | 2014 | 1526 | 0.470 |
Why?
|
Rubidium Radioisotopes | 1 | 2014 | 97 | 0.470 |
Why?
|
Pulmonary Wedge Pressure | 5 | 2021 | 277 | 0.460 |
Why?
|
Prognosis | 34 | 2021 | 30009 | 0.450 |
Why?
|
Urocortins | 1 | 2013 | 20 | 0.450 |
Why?
|
Disease Management | 8 | 2017 | 2535 | 0.450 |
Why?
|
Ventricular Pressure | 2 | 2012 | 210 | 0.450 |
Why?
|
Heart Defects, Congenital | 4 | 2019 | 4712 | 0.440 |
Why?
|
Cystatin C | 5 | 2016 | 272 | 0.440 |
Why?
|
International Normalized Ratio | 5 | 2024 | 382 | 0.430 |
Why?
|
Gout | 2 | 2018 | 621 | 0.430 |
Why?
|
Aged | 96 | 2024 | 171502 | 0.430 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2020 | 10397 | 0.420 |
Why?
|
Diuresis | 2 | 2016 | 107 | 0.420 |
Why?
|
Arrhythmias, Cardiac | 2 | 2015 | 2258 | 0.420 |
Why?
|
Inferior Wall Myocardial Infarction | 1 | 2012 | 10 | 0.420 |
Why?
|
Puerperal Disorders | 3 | 2023 | 304 | 0.410 |
Why?
|
Health Resources | 1 | 2019 | 950 | 0.410 |
Why?
|
Severity of Illness Index | 15 | 2021 | 15949 | 0.400 |
Why?
|
Cardiac Pacing, Artificial | 4 | 2012 | 881 | 0.400 |
Why?
|
Heart Aneurysm | 1 | 2012 | 114 | 0.400 |
Why?
|
Endothelins | 3 | 2002 | 127 | 0.400 |
Why?
|
Oxygen Consumption | 6 | 2018 | 1880 | 0.400 |
Why?
|
Glomerular Filtration Rate | 10 | 2020 | 2227 | 0.390 |
Why?
|
Kidney Failure, Chronic | 4 | 2014 | 2496 | 0.390 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2016 | 317 | 0.390 |
Why?
|
Coronary Angiography | 4 | 2018 | 4541 | 0.380 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2019 | 1126 | 0.380 |
Why?
|
Survival Rate | 16 | 2019 | 12840 | 0.380 |
Why?
|
Risk Adjustment | 1 | 2015 | 599 | 0.370 |
Why?
|
Specialization | 1 | 2016 | 779 | 0.370 |
Why?
|
Thromboembolism | 4 | 2024 | 1004 | 0.370 |
Why?
|
Vascular Diseases | 3 | 2019 | 1162 | 0.360 |
Why?
|
End Stage Liver Disease | 1 | 2015 | 370 | 0.350 |
Why?
|
Relaxin | 3 | 2016 | 42 | 0.350 |
Why?
|
Coronary Artery Disease | 5 | 2017 | 6568 | 0.350 |
Why?
|
Sarcoidosis | 2 | 2019 | 535 | 0.350 |
Why?
|
Heart Valve Prosthesis | 1 | 2018 | 1468 | 0.340 |
Why?
|
Disease Progression | 17 | 2019 | 13668 | 0.340 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 1798 | 0.340 |
Why?
|
Heterocyclic Compounds, 2-Ring | 1 | 2009 | 38 | 0.330 |
Why?
|
Risk Assessment | 18 | 2024 | 24318 | 0.330 |
Why?
|
Assisted Circulation | 2 | 2023 | 100 | 0.330 |
Why?
|
Lymphoproliferative Disorders | 1 | 2013 | 528 | 0.330 |
Why?
|
Peptide Fragments | 9 | 2022 | 5151 | 0.330 |
Why?
|
Dose-Response Relationship, Drug | 13 | 2020 | 10763 | 0.330 |
Why?
|
Cyclohexanes | 1 | 2009 | 152 | 0.330 |
Why?
|
Tunica Intima | 1 | 2011 | 459 | 0.330 |
Why?
|
Cardiovascular Diseases | 8 | 2020 | 15662 | 0.320 |
Why?
|
Advisory Committees | 4 | 2017 | 796 | 0.320 |
Why?
|
Shock, Cardiogenic | 3 | 2024 | 711 | 0.320 |
Why?
|
Blood Coagulation Factors | 2 | 2024 | 371 | 0.320 |
Why?
|
Anticoagulants | 6 | 2024 | 4850 | 0.320 |
Why?
|
Fontan Procedure | 1 | 2015 | 805 | 0.310 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2014 | 672 | 0.310 |
Why?
|
Self Care | 2 | 2011 | 799 | 0.300 |
Why?
|
Thrombosis | 6 | 2019 | 2957 | 0.300 |
Why?
|
Natriuretic Agents | 3 | 2013 | 57 | 0.300 |
Why?
|
Ascorbic Acid | 1 | 2011 | 658 | 0.300 |
Why?
|
Patient Compliance | 1 | 2018 | 2697 | 0.300 |
Why?
|
Retrospective Studies | 34 | 2024 | 81760 | 0.300 |
Why?
|
Biopsy | 4 | 2017 | 6792 | 0.290 |
Why?
|
Prediabetic State | 1 | 2013 | 548 | 0.290 |
Why?
|
Intra-Aortic Balloon Pumping | 4 | 2023 | 223 | 0.290 |
Why?
|
Emergency Medical Services | 1 | 2019 | 1947 | 0.290 |
Why?
|
Hypertension, Pulmonary | 4 | 2012 | 1605 | 0.290 |
Why?
|
Hypoglycemic Agents | 3 | 2019 | 3109 | 0.290 |
Why?
|
Follow-Up Studies | 20 | 2024 | 39354 | 0.290 |
Why?
|
Patient Care Team | 1 | 2018 | 2523 | 0.280 |
Why?
|
Vitamin E | 1 | 2011 | 874 | 0.280 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 428 | 0.280 |
Why?
|
Dopamine | 4 | 2016 | 1592 | 0.280 |
Why?
|
Dyspnea | 8 | 2016 | 1352 | 0.270 |
Why?
|
Iron Compounds | 2 | 2017 | 28 | 0.270 |
Why?
|
Liver Cirrhosis | 2 | 2015 | 1960 | 0.270 |
Why?
|
Protein Precursors | 3 | 2016 | 1135 | 0.270 |
Why?
|
Time Factors | 30 | 2024 | 40220 | 0.270 |
Why?
|
Hydrazones | 1 | 2007 | 105 | 0.270 |
Why?
|
Myocarditis | 2 | 2013 | 802 | 0.270 |
Why?
|
Predictive Value of Tests | 21 | 2019 | 15453 | 0.270 |
Why?
|
Ventricular Function, Right | 4 | 2017 | 629 | 0.270 |
Why?
|
United States | 36 | 2024 | 73039 | 0.260 |
Why?
|
Heart Neoplasms | 1 | 2010 | 374 | 0.260 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2019 | 12252 | 0.260 |
Why?
|
Adult | 53 | 2024 | 223646 | 0.260 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2017 | 2298 | 0.260 |
Why?
|
Blood Urea Nitrogen | 3 | 2016 | 189 | 0.260 |
Why?
|
Positron-Emission Tomography | 4 | 2021 | 6669 | 0.260 |
Why?
|
Heart | 6 | 2023 | 4446 | 0.250 |
Why?
|
Radiopharmaceuticals | 2 | 2019 | 2735 | 0.250 |
Why?
|
Transplantation, Homologous | 2 | 2017 | 4834 | 0.250 |
Why?
|
Proportional Hazards Models | 17 | 2019 | 12543 | 0.250 |
Why?
|
Women's Health | 1 | 2015 | 2082 | 0.250 |
Why?
|
Ventricular Remodeling | 4 | 2018 | 1282 | 0.250 |
Why?
|
Pyridazines | 1 | 2007 | 203 | 0.240 |
Why?
|
Echocardiography | 6 | 2014 | 5047 | 0.240 |
Why?
|
Adrenomedullin | 3 | 2019 | 85 | 0.240 |
Why?
|
Risk Factors | 28 | 2020 | 74944 | 0.240 |
Why?
|
Hospital Mortality | 7 | 2024 | 5349 | 0.240 |
Why?
|
Pleural Neoplasms | 1 | 2010 | 612 | 0.240 |
Why?
|
Heart Conduction System | 1 | 2010 | 1009 | 0.240 |
Why?
|
Ambulatory Care | 5 | 2018 | 2783 | 0.240 |
Why?
|
Immunosuppressive Agents | 5 | 2020 | 4206 | 0.230 |
Why?
|
Extracorporeal Membrane Oxygenation | 5 | 2024 | 1483 | 0.230 |
Why?
|
Aged, 80 and over | 31 | 2021 | 59626 | 0.230 |
Why?
|
Phosphodiesterase 5 Inhibitors | 2 | 2016 | 103 | 0.230 |
Why?
|
Prosthesis Design | 5 | 2019 | 2125 | 0.230 |
Why?
|
Medical Oncology | 1 | 2016 | 2346 | 0.230 |
Why?
|
Pulmonary Circulation | 3 | 2002 | 745 | 0.230 |
Why?
|
Serum Albumin | 3 | 2016 | 677 | 0.230 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3415 | 0.220 |
Why?
|
Biphenyl Compounds | 3 | 2022 | 1026 | 0.220 |
Why?
|
Hepacivirus | 3 | 2022 | 1344 | 0.220 |
Why?
|
Immunocompromised Host | 3 | 2020 | 863 | 0.220 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2420 | 0.220 |
Why?
|
Mesothelioma | 1 | 2010 | 811 | 0.220 |
Why?
|
Valsalva Maneuver | 2 | 2001 | 99 | 0.220 |
Why?
|
Lung Transplantation | 3 | 2023 | 1309 | 0.220 |
Why?
|
Sodium | 5 | 2019 | 1597 | 0.210 |
Why?
|
Algorithms | 5 | 2020 | 14164 | 0.210 |
Why?
|
Prospective Studies | 20 | 2024 | 54924 | 0.210 |
Why?
|
Uric Acid | 3 | 2021 | 805 | 0.210 |
Why?
|
Blood Pressure | 12 | 2023 | 8543 | 0.200 |
Why?
|
Spironolactone | 4 | 2020 | 415 | 0.200 |
Why?
|
Acute Kidney Injury | 2 | 2017 | 1942 | 0.200 |
Why?
|
Adrenergic beta-Agonists | 2 | 2001 | 347 | 0.200 |
Why?
|
Ambulatory Care Facilities | 1 | 2008 | 939 | 0.200 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5520 | 0.190 |
Why?
|
Oxidative Stress | 4 | 2015 | 3140 | 0.190 |
Why?
|
Organ Preservation | 2 | 2023 | 393 | 0.190 |
Why?
|
Research Design | 4 | 2016 | 6209 | 0.190 |
Why?
|
Diagnostic Techniques, Cardiovascular | 2 | 2019 | 153 | 0.190 |
Why?
|
Extracorporeal Circulation | 1 | 2022 | 181 | 0.190 |
Why?
|
Heart Rate | 4 | 2022 | 4214 | 0.190 |
Why?
|
Ultrafiltration | 2 | 2012 | 48 | 0.190 |
Why?
|
Vascular Resistance | 4 | 2012 | 939 | 0.180 |
Why?
|
Mortality | 6 | 2018 | 2911 | 0.180 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5367 | 0.180 |
Why?
|
Isoxazoles | 1 | 2002 | 233 | 0.180 |
Why?
|
Length of Stay | 6 | 2019 | 6498 | 0.180 |
Why?
|
Pacemaker, Artificial | 1 | 2006 | 828 | 0.180 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2018 | 1091 | 0.180 |
Why?
|
Mitral Valve Insufficiency | 3 | 2023 | 1415 | 0.180 |
Why?
|
Annexin A1 | 1 | 2020 | 22 | 0.180 |
Why?
|
Antihypertensive Agents | 2 | 2008 | 2029 | 0.180 |
Why?
|
Infusions, Intravenous | 5 | 2012 | 2230 | 0.170 |
Why?
|
Comorbidity | 9 | 2017 | 10590 | 0.170 |
Why?
|
Receptor, Adenosine A1 | 2 | 2010 | 42 | 0.170 |
Why?
|
Critical Care | 2 | 2012 | 2715 | 0.170 |
Why?
|
Renal Circulation | 2 | 2015 | 291 | 0.170 |
Why?
|
Tetrazoles | 2 | 2020 | 923 | 0.170 |
Why?
|
Stroke | 5 | 2023 | 9755 | 0.170 |
Why?
|
Neurotransmitter Agents | 1 | 2004 | 663 | 0.170 |
Why?
|
Brain Death | 1 | 2023 | 359 | 0.170 |
Why?
|
Syndrome | 4 | 2012 | 3273 | 0.170 |
Why?
|
Cardiovascular System | 2 | 2017 | 841 | 0.170 |
Why?
|
Coronary Vessels | 4 | 2020 | 3124 | 0.160 |
Why?
|
Vasodilation | 2 | 2000 | 967 | 0.160 |
Why?
|
Liver | 1 | 2015 | 7578 | 0.160 |
Why?
|
Pandemics | 6 | 2020 | 8747 | 0.160 |
Why?
|
Hypertension | 5 | 2023 | 8616 | 0.160 |
Why?
|
Cardiac Surgical Procedures | 2 | 2024 | 3684 | 0.160 |
Why?
|
Hemoglobins | 2 | 2016 | 1531 | 0.150 |
Why?
|
Pilot Projects | 6 | 2024 | 8741 | 0.150 |
Why?
|
Nitrites | 1 | 2018 | 156 | 0.150 |
Why?
|
Genetics, Medical | 2 | 2018 | 334 | 0.150 |
Why?
|
Drug Resistance | 3 | 2016 | 1599 | 0.150 |
Why?
|
Probenecid | 1 | 2018 | 73 | 0.150 |
Why?
|
Recovery of Function | 7 | 2019 | 2981 | 0.150 |
Why?
|
Thiophenes | 1 | 2002 | 570 | 0.150 |
Why?
|
Methylation | 1 | 2021 | 1078 | 0.150 |
Why?
|
Blood Pressure Monitors | 1 | 2017 | 33 | 0.150 |
Why?
|
Fibrinolytic Agents | 2 | 2024 | 2080 | 0.150 |
Why?
|
Heart Function Tests | 2 | 2009 | 317 | 0.140 |
Why?
|
Carbamates | 1 | 2019 | 192 | 0.140 |
Why?
|
Directive Counseling | 1 | 2019 | 171 | 0.140 |
Why?
|
Cachexia | 1 | 2019 | 202 | 0.140 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 3 | 2019 | 158 | 0.140 |
Why?
|
Genetic Counseling | 2 | 2018 | 635 | 0.140 |
Why?
|
Hyperkalemia | 1 | 2019 | 234 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor C | 2 | 2019 | 125 | 0.140 |
Why?
|
Oxypurinol | 2 | 2008 | 8 | 0.140 |
Why?
|
Perfusion | 1 | 2022 | 1401 | 0.140 |
Why?
|
Atrial Natriuretic Factor | 2 | 2013 | 350 | 0.140 |
Why?
|
Benzazepines | 2 | 2016 | 308 | 0.140 |
Why?
|
Activities of Daily Living | 2 | 2019 | 2430 | 0.140 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2024 | 997 | 0.140 |
Why?
|
Coronary Circulation | 3 | 2008 | 1617 | 0.130 |
Why?
|
Cohort Studies | 12 | 2024 | 41753 | 0.130 |
Why?
|
Enkephalins | 1 | 2016 | 139 | 0.130 |
Why?
|
Vitamin K | 1 | 2019 | 314 | 0.130 |
Why?
|
Contrast Media | 3 | 2018 | 5330 | 0.130 |
Why?
|
Intracranial Hemorrhages | 2 | 2019 | 809 | 0.130 |
Why?
|
Outpatients | 4 | 2013 | 1600 | 0.130 |
Why?
|
Hemofiltration | 2 | 2013 | 58 | 0.130 |
Why?
|
Intention to Treat Analysis | 3 | 2011 | 416 | 0.130 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2016 | 89 | 0.130 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 245 | 0.130 |
Why?
|
Pregnancy | 8 | 2023 | 30255 | 0.130 |
Why?
|
Incidence | 8 | 2020 | 21538 | 0.130 |
Why?
|
MicroRNAs | 3 | 2016 | 3803 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2019 | 3517 | 0.130 |
Why?
|
Nutrition Assessment | 1 | 2019 | 740 | 0.130 |
Why?
|
Survival Analysis | 6 | 2016 | 10099 | 0.130 |
Why?
|
Death, Sudden, Cardiac | 3 | 2015 | 1567 | 0.120 |
Why?
|
Gadolinium DTPA | 1 | 2018 | 823 | 0.120 |
Why?
|
Nitrates | 1 | 2016 | 260 | 0.120 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2023 | 1566 | 0.120 |
Why?
|
Endothelium, Vascular | 2 | 2013 | 4428 | 0.120 |
Why?
|
International Cooperation | 2 | 2019 | 1436 | 0.120 |
Why?
|
Nitric Oxide | 2 | 2002 | 2149 | 0.120 |
Why?
|
Urination | 1 | 2016 | 204 | 0.120 |
Why?
|
Brain Ischemia | 2 | 2019 | 3007 | 0.120 |
Why?
|
Genetic Testing | 2 | 2018 | 3591 | 0.120 |
Why?
|
Infusions, Intra-Arterial | 2 | 2007 | 220 | 0.120 |
Why?
|
Oxidation-Reduction | 1 | 2021 | 2227 | 0.120 |
Why?
|
Antiviral Agents | 4 | 2022 | 3072 | 0.120 |
Why?
|
Glucosides | 1 | 2019 | 533 | 0.120 |
Why?
|
Aspartate Aminotransferases | 1 | 2016 | 414 | 0.120 |
Why?
|
Calcitonin | 1 | 2015 | 329 | 0.120 |
Why?
|
Hepatitis C, Chronic | 1 | 2022 | 1032 | 0.120 |
Why?
|
Sulfonamides | 3 | 2015 | 1982 | 0.120 |
Why?
|
Ferritins | 1 | 2017 | 601 | 0.110 |
Why?
|
Urea | 2 | 2013 | 448 | 0.110 |
Why?
|
Risk | 4 | 2020 | 9613 | 0.110 |
Why?
|
Heart Atria | 3 | 2021 | 1361 | 0.110 |
Why?
|
Cardiotoxins | 1 | 2013 | 36 | 0.110 |
Why?
|
Guideline Adherence | 1 | 2024 | 2235 | 0.110 |
Why?
|
Exercise Test | 3 | 2018 | 2186 | 0.110 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1255 | 0.110 |
Why?
|
Multivariate Analysis | 7 | 2016 | 12077 | 0.110 |
Why?
|
Prolactin | 1 | 2016 | 627 | 0.110 |
Why?
|
Tissue Survival | 1 | 2014 | 120 | 0.110 |
Why?
|
Coronary Vessel Anomalies | 1 | 2017 | 308 | 0.110 |
Why?
|
Neuralgia, Postherpetic | 1 | 2013 | 41 | 0.110 |
Why?
|
Potassium | 2 | 2016 | 1315 | 0.110 |
Why?
|
Chlorides | 1 | 2016 | 666 | 0.110 |
Why?
|
Organometallic Compounds | 1 | 2017 | 648 | 0.110 |
Why?
|
Gout Suppressants | 1 | 2015 | 176 | 0.110 |
Why?
|
Alanine Transaminase | 1 | 2016 | 606 | 0.110 |
Why?
|
Hematinics | 1 | 2016 | 282 | 0.110 |
Why?
|
Remission, Spontaneous | 1 | 2013 | 384 | 0.110 |
Why?
|
Enzyme Inhibitors | 3 | 2016 | 3728 | 0.110 |
Why?
|
Aortic Stenosis, Supravalvular | 1 | 2012 | 28 | 0.100 |
Why?
|
Defibrillators, Implantable | 2 | 2015 | 1498 | 0.100 |
Why?
|
Bariatric Surgery | 2 | 2020 | 1001 | 0.100 |
Why?
|
Antioxidants | 1 | 2001 | 1676 | 0.100 |
Why?
|
Heart Rupture, Post-Infarction | 1 | 2012 | 48 | 0.100 |
Why?
|
Saline Solution, Hypertonic | 1 | 2013 | 115 | 0.100 |
Why?
|
Ultrasonography | 2 | 2017 | 6004 | 0.100 |
Why?
|
Benzhydryl Compounds | 1 | 2019 | 944 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 560 | 0.100 |
Why?
|
Young Adult | 12 | 2019 | 60066 | 0.100 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2019 | 888 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2023 | 2763 | 0.100 |
Why?
|
Bumetanide | 2 | 2014 | 101 | 0.100 |
Why?
|
Kidney Function Tests | 4 | 2017 | 684 | 0.100 |
Why?
|
Atrial Septum | 1 | 2012 | 61 | 0.100 |
Why?
|
Endpoint Determination | 1 | 2015 | 592 | 0.100 |
Why?
|
Nitroglycerin | 1 | 2013 | 332 | 0.100 |
Why?
|
Canada | 4 | 2022 | 2130 | 0.100 |
Why?
|
Chromogranin A | 1 | 2011 | 47 | 0.100 |
Why?
|
Administration, Oral | 3 | 2017 | 4034 | 0.100 |
Why?
|
Drug Administration Schedule | 3 | 2020 | 4861 | 0.100 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2016 | 372 | 0.100 |
Why?
|
Receptor, Endothelin A | 2 | 2002 | 55 | 0.100 |
Why?
|
Glycopeptides | 1 | 2013 | 225 | 0.100 |
Why?
|
Action Potentials | 1 | 2019 | 1838 | 0.090 |
Why?
|
Equipment Failure | 1 | 2014 | 585 | 0.090 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 348 | 0.090 |
Why?
|
Diet, Sodium-Restricted | 1 | 2013 | 291 | 0.090 |
Why?
|
Mycoses | 1 | 2014 | 386 | 0.090 |
Why?
|
Pyridones | 1 | 1996 | 819 | 0.090 |
Why?
|
Herpes Zoster | 1 | 2013 | 252 | 0.090 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2013 | 254 | 0.090 |
Why?
|
Resistin | 1 | 2011 | 172 | 0.090 |
Why?
|
Interleukin-6 | 1 | 2021 | 3229 | 0.090 |
Why?
|
Lipocalins | 1 | 2011 | 161 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2015 | 1194 | 0.090 |
Why?
|
Biomedical Research | 3 | 2016 | 3463 | 0.090 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2019 | 2055 | 0.090 |
Why?
|
Sulfones | 1 | 2013 | 448 | 0.090 |
Why?
|
Reactive Oxygen Species | 2 | 2013 | 2152 | 0.090 |
Why?
|
Acute-Phase Proteins | 1 | 2011 | 252 | 0.090 |
Why?
|
Graft Survival | 3 | 2023 | 3887 | 0.090 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8052 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1596 | 0.090 |
Why?
|
Echocardiography, Doppler, Pulsed | 1 | 2009 | 69 | 0.080 |
Why?
|
Myocardial Infarction | 4 | 2021 | 11519 | 0.080 |
Why?
|
Subtraction Technique | 1 | 2012 | 517 | 0.080 |
Why?
|
Syncope | 1 | 2012 | 430 | 0.080 |
Why?
|
Galectin 3 | 1 | 2011 | 240 | 0.080 |
Why?
|
Mitochondria, Heart | 1 | 2011 | 236 | 0.080 |
Why?
|
Treatment Failure | 3 | 2018 | 2661 | 0.080 |
Why?
|
Feasibility Studies | 2 | 2019 | 5315 | 0.080 |
Why?
|
Polysaccharides | 1 | 2016 | 1024 | 0.080 |
Why?
|
Receptors, Vasopressin | 1 | 2009 | 106 | 0.080 |
Why?
|
Sex Characteristics | 1 | 2020 | 2649 | 0.080 |
Why?
|
Research | 1 | 2017 | 1979 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2016 | 6525 | 0.080 |
Why?
|
Health Status Indicators | 3 | 2010 | 969 | 0.080 |
Why?
|
Obesity, Morbid | 1 | 2020 | 1298 | 0.080 |
Why?
|
Device Removal | 1 | 2014 | 643 | 0.080 |
Why?
|
Adult Stem Cells | 1 | 2011 | 221 | 0.080 |
Why?
|
Diabetes Mellitus | 3 | 2017 | 5891 | 0.080 |
Why?
|
Aortic Valve | 1 | 2018 | 1970 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1140 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1397 | 0.080 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1178 | 0.080 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2013 | 621 | 0.080 |
Why?
|
Chronic Disease | 5 | 2015 | 9384 | 0.080 |
Why?
|
Leptin | 2 | 2018 | 1599 | 0.080 |
Why?
|
Cardiomegaly | 1 | 2011 | 591 | 0.070 |
Why?
|
Electrocardiography | 2 | 2019 | 6412 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 1 | 2013 | 789 | 0.070 |
Why?
|
B-Lymphocytes | 2 | 2019 | 4793 | 0.070 |
Why?
|
Troponin | 1 | 2011 | 535 | 0.070 |
Why?
|
Coronary Stenosis | 1 | 2013 | 802 | 0.070 |
Why?
|
Bacterial Infections | 1 | 2015 | 1397 | 0.070 |
Why?
|
Cytokines | 2 | 2021 | 7452 | 0.070 |
Why?
|
Age Factors | 6 | 2019 | 18415 | 0.070 |
Why?
|
Neoplasms | 1 | 2016 | 22371 | 0.070 |
Why?
|
Home Care Services | 1 | 2013 | 659 | 0.070 |
Why?
|
Massachusetts | 2 | 2017 | 8890 | 0.070 |
Why?
|
Blood Volume | 1 | 2008 | 545 | 0.070 |
Why?
|
Heparin | 1 | 2014 | 1636 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3721 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 13013 | 0.070 |
Why?
|
Cerebral Hemorrhage | 1 | 2018 | 2654 | 0.070 |
Why?
|
Health Care Costs | 1 | 2019 | 3239 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 4 | 2019 | 36741 | 0.070 |
Why?
|
Quality Improvement | 2 | 2020 | 3857 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2016 | 2008 | 0.060 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2012 | 560 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 3814 | 0.060 |
Why?
|
Sex Factors | 4 | 2014 | 10632 | 0.060 |
Why?
|
Thoracoscopy | 1 | 2006 | 186 | 0.060 |
Why?
|
Animals | 8 | 2019 | 169285 | 0.060 |
Why?
|
Adiponectin | 1 | 2011 | 1117 | 0.060 |
Why?
|
Drug Therapy, Combination | 3 | 2013 | 6316 | 0.060 |
Why?
|
Recurrence | 2 | 2017 | 8509 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3251 | 0.060 |
Why?
|
Retreatment | 1 | 2006 | 598 | 0.060 |
Why?
|
Thoracotomy | 1 | 2006 | 374 | 0.060 |
Why?
|
Drug Combinations | 2 | 2022 | 2089 | 0.060 |
Why?
|
Body Mass Index | 3 | 2018 | 13053 | 0.060 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2011 | 1724 | 0.060 |
Why?
|
Benzimidazoles | 1 | 2010 | 864 | 0.060 |
Why?
|
Oxygen | 1 | 2016 | 4270 | 0.060 |
Why?
|
Exercise | 2 | 2000 | 5954 | 0.060 |
Why?
|
Probability | 1 | 2009 | 2479 | 0.060 |
Why?
|
Mitral Valve | 1 | 2012 | 1475 | 0.060 |
Why?
|
Research Report | 2 | 2017 | 369 | 0.060 |
Why?
|
Chest Pain | 1 | 2011 | 1101 | 0.060 |
Why?
|
Hypotension | 3 | 2020 | 888 | 0.050 |
Why?
|
Anemia | 1 | 2013 | 1514 | 0.050 |
Why?
|
Troponin I | 1 | 2007 | 662 | 0.050 |
Why?
|
Ventricular Function | 2 | 2015 | 406 | 0.050 |
Why?
|
Case Management | 1 | 2005 | 277 | 0.050 |
Why?
|
Systole | 3 | 2014 | 937 | 0.050 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3436 | 0.050 |
Why?
|
Reproducibility of Results | 5 | 2019 | 20225 | 0.050 |
Why?
|
Patient Education as Topic | 2 | 2009 | 2337 | 0.050 |
Why?
|
Logistic Models | 5 | 2016 | 13290 | 0.050 |
Why?
|
Reference Values | 2 | 2016 | 4939 | 0.050 |
Why?
|
Piperazines | 1 | 2013 | 2554 | 0.050 |
Why?
|
Atherosclerosis | 2 | 2015 | 3433 | 0.050 |
Why?
|
Pain Measurement | 1 | 2012 | 3583 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 2819 | 0.050 |
Why?
|
Electrodes, Implanted | 1 | 2006 | 836 | 0.050 |
Why?
|
Vasomotor System | 1 | 2002 | 208 | 0.050 |
Why?
|
Injections, Intravenous | 2 | 2011 | 1379 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2020 | 1737 | 0.050 |
Why?
|
Models, Cardiovascular | 2 | 2017 | 981 | 0.050 |
Why?
|
Blood Glucose | 1 | 2016 | 6431 | 0.050 |
Why?
|
Odds Ratio | 4 | 2016 | 9669 | 0.050 |
Why?
|
Respiration, Artificial | 1 | 2012 | 2726 | 0.050 |
Why?
|
Antigens, CD | 1 | 2011 | 4035 | 0.040 |
Why?
|
Adolescent | 7 | 2022 | 89169 | 0.040 |
Why?
|
Donor Selection | 1 | 2022 | 240 | 0.040 |
Why?
|
Early Termination of Clinical Trials | 1 | 2020 | 70 | 0.040 |
Why?
|
Aortic Valve Stenosis | 1 | 2012 | 2032 | 0.040 |
Why?
|
Ultrasonography, Doppler | 1 | 2022 | 463 | 0.040 |
Why?
|
Weight Loss | 3 | 2019 | 2721 | 0.040 |
Why?
|
Inorganic Chemicals | 1 | 2018 | 10 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 4528 | 0.040 |
Why?
|
Clinical Protocols | 2 | 2016 | 1443 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2011 | 1885 | 0.040 |
Why?
|
Hemorrhage | 2 | 2023 | 3466 | 0.040 |
Why?
|
Hepatitis C Antibodies | 1 | 2019 | 151 | 0.040 |
Why?
|
Bronchodilator Agents | 1 | 2002 | 518 | 0.040 |
Why?
|
Endothelin-1 | 1 | 2000 | 296 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 2002 | 1375 | 0.040 |
Why?
|
Death | 1 | 2023 | 683 | 0.040 |
Why?
|
Emergency Service, Hospital | 2 | 2016 | 7951 | 0.040 |
Why?
|
India | 2 | 2015 | 2334 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2013 | 4310 | 0.040 |
Why?
|
Vimentin | 1 | 2019 | 257 | 0.040 |
Why?
|
Infant, Newborn | 3 | 2013 | 26421 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 614 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 8542 | 0.040 |
Why?
|
Genetics | 1 | 2018 | 114 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11930 | 0.040 |
Why?
|
Norepinephrine | 1 | 2000 | 898 | 0.040 |
Why?
|
Myocardial Ischemia | 2 | 2016 | 2138 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 3706 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18349 | 0.040 |
Why?
|
Models, Biological | 1 | 2013 | 9497 | 0.040 |
Why?
|
Myosins | 1 | 2019 | 408 | 0.040 |
Why?
|
Milrinone | 1 | 1996 | 86 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 13091 | 0.030 |
Why?
|
Diet | 1 | 2014 | 8089 | 0.030 |
Why?
|
Postpartum Period | 1 | 2023 | 1197 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2013 | 2923 | 0.030 |
Why?
|
Transferrin | 1 | 2017 | 283 | 0.030 |
Why?
|
Europe | 2 | 2015 | 3436 | 0.030 |
Why?
|
Acetylglucosaminidase | 1 | 2015 | 66 | 0.030 |
Why?
|
Micronutrients | 1 | 2019 | 390 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2022 | 1741 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2018 | 1169 | 0.030 |
Why?
|
Anti-Obesity Agents | 1 | 2019 | 240 | 0.030 |
Why?
|
Protective Agents | 1 | 2016 | 151 | 0.030 |
Why?
|
North America | 1 | 2019 | 1289 | 0.030 |
Why?
|
Nitric Oxide Synthase | 1 | 1998 | 911 | 0.030 |
Why?
|
Th17 Cells | 1 | 2021 | 791 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2016 | 526 | 0.030 |
Why?
|
Heart Arrest | 1 | 2024 | 1515 | 0.030 |
Why?
|
Electrolytes | 1 | 2015 | 279 | 0.030 |
Why?
|
Europe, Eastern | 1 | 2014 | 72 | 0.030 |
Why?
|
Cardiac Output | 1 | 1996 | 838 | 0.030 |
Why?
|
Plasma Cells | 1 | 2017 | 599 | 0.030 |
Why?
|
Sarcopenia | 1 | 2019 | 378 | 0.030 |
Why?
|
Drug Interactions | 1 | 2018 | 1419 | 0.030 |
Why?
|
Latin America | 1 | 2015 | 416 | 0.030 |
Why?
|
Dietary Proteins | 1 | 2019 | 960 | 0.030 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2013 | 37 | 0.030 |
Why?
|
Kidney Tubules | 1 | 2015 | 454 | 0.030 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2014 | 184 | 0.030 |
Why?
|
Genotype | 2 | 2018 | 13045 | 0.030 |
Why?
|
Immune System | 1 | 2019 | 800 | 0.030 |
Why?
|
Russia | 1 | 2014 | 386 | 0.030 |
Why?
|
HLA Antigens | 1 | 2019 | 1334 | 0.030 |
Why?
|
Natriuretic Peptides | 1 | 2014 | 156 | 0.030 |
Why?
|
Incidental Findings | 1 | 2018 | 698 | 0.030 |
Why?
|
Ganciclovir | 1 | 2013 | 256 | 0.030 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2015 | 328 | 0.030 |
Why?
|
Fatigue | 2 | 2016 | 1557 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1119 | 0.030 |
Why?
|
Malnutrition | 1 | 2019 | 632 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2020 | 1738 | 0.030 |
Why?
|
Urine | 1 | 2013 | 362 | 0.020 |
Why?
|
Postoperative Care | 1 | 2019 | 1480 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2018 | 2107 | 0.020 |
Why?
|
T-Lymphocytes | 2 | 2020 | 10266 | 0.020 |
Why?
|
Health Status | 2 | 2017 | 4091 | 0.020 |
Why?
|
Netherlands | 1 | 2017 | 2277 | 0.020 |
Why?
|
Edema | 1 | 2016 | 765 | 0.020 |
Why?
|
Diet, Mediterranean | 1 | 2019 | 748 | 0.020 |
Why?
|
Gadolinium | 1 | 2017 | 964 | 0.020 |
Why?
|
Geography | 1 | 2014 | 652 | 0.020 |
Why?
|
Vasoconstrictor Agents | 1 | 2015 | 656 | 0.020 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2012 | 213 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2019 | 1835 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 878 | 0.020 |
Why?
|
Counseling | 1 | 2019 | 1554 | 0.020 |
Why?
|
Random Allocation | 1 | 2015 | 2395 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2017 | 1474 | 0.020 |
Why?
|
Metoprolol | 1 | 2011 | 90 | 0.020 |
Why?
|
RNA, Viral | 1 | 2019 | 2874 | 0.020 |
Why?
|
Organ Size | 1 | 2015 | 2267 | 0.020 |
Why?
|
Mitral Valve Stenosis | 1 | 2012 | 342 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16726 | 0.020 |
Why?
|
Echocardiography, Doppler | 1 | 2014 | 898 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2010 | 367 | 0.020 |
Why?
|
Fibrosis | 1 | 2017 | 2081 | 0.020 |
Why?
|
Purines | 1 | 2013 | 615 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2022 | 5536 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 26379 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20762 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2939 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3628 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2000 | 4355 | 0.020 |
Why?
|
Physical Examination | 1 | 2014 | 1263 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2019 | 2631 | 0.020 |
Why?
|
Internationality | 1 | 2014 | 1008 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4585 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 1321 | 0.020 |
Why?
|
Italy | 1 | 2010 | 856 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2017 | 6231 | 0.020 |
Why?
|
Aldosterone | 1 | 2012 | 881 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2014 | 1320 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2013 | 837 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1643 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5884 | 0.020 |
Why?
|
Cost of Illness | 1 | 2016 | 1951 | 0.020 |
Why?
|
Diastole | 1 | 2008 | 785 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2012 | 2357 | 0.020 |
Why?
|
Walking | 1 | 2013 | 1201 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2014 | 6229 | 0.020 |
Why?
|
Prevalence | 2 | 2018 | 15869 | 0.020 |
Why?
|
Forecasting | 1 | 2014 | 2945 | 0.020 |
Why?
|
Telomere | 1 | 2011 | 943 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2008 | 1587 | 0.010 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2005 | 111 | 0.010 |
Why?
|
Boston | 2 | 2010 | 9374 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14729 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11095 | 0.010 |
Why?
|
Lung | 1 | 2002 | 10101 | 0.010 |
Why?
|
Benzothiadiazines | 1 | 2003 | 31 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2013 | 6512 | 0.010 |
Why?
|
Hearing Loss | 1 | 2011 | 785 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2011 | 2434 | 0.010 |
Why?
|
Coronary Disease | 1 | 2018 | 5919 | 0.010 |
Why?
|
Hyponatremia | 1 | 2006 | 279 | 0.010 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2003 | 78 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9540 | 0.010 |
Why?
|
Life Expectancy | 1 | 2009 | 1248 | 0.010 |
Why?
|
Macrophages | 1 | 2017 | 5802 | 0.010 |
Why?
|
Mass Screening | 1 | 2018 | 5458 | 0.010 |
Why?
|
Genomics | 1 | 2018 | 5926 | 0.010 |
Why?
|
Telephone | 1 | 2005 | 630 | 0.010 |
Why?
|
Income | 1 | 2010 | 1878 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2271 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2014 | 3390 | 0.010 |
Why?
|
Office Visits | 1 | 2005 | 595 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 8080 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2010 | 1791 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 3252 | 0.010 |
Why?
|
Equipment Design | 1 | 2008 | 3522 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2010 | 2118 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 6986 | 0.010 |
Why?
|
Patient Admission | 1 | 2007 | 1365 | 0.010 |
Why?
|
Vital Capacity | 1 | 2002 | 996 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2008 | 1238 | 0.010 |
Why?
|
Infant | 2 | 2011 | 36535 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22380 | 0.010 |
Why?
|
omega-N-Methylarginine | 1 | 1998 | 108 | 0.010 |
Why?
|
Dobutamine | 1 | 1998 | 116 | 0.010 |
Why?
|
Signal Transduction | 1 | 2001 | 23648 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22290 | 0.010 |
Why?
|
Models, Statistical | 1 | 2012 | 5107 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3490 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2010 | 7852 | 0.010 |
Why?
|
Acetylcholine | 1 | 1998 | 629 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2011 | 19025 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2011 | 10478 | 0.010 |
Why?
|
Drug Synergism | 1 | 1998 | 1760 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2011 | 11677 | 0.010 |
Why?
|
Child | 2 | 2011 | 80917 | 0.010 |
Why?
|
Decision Making | 1 | 2004 | 3953 | 0.010 |
Why?
|
Mice | 1 | 2017 | 82049 | 0.010 |
Why?
|
Child, Preschool | 1 | 2011 | 42669 | 0.000 |
Why?
|
Internship and Residency | 1 | 2008 | 5953 | 0.000 |
Why?
|